


**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)  
(Use several sheets if necessary)



**COMPLETE IF KNOWN**

Application Number	10/821,021
Confirmation Number	9232
Filing Date	April 7, 2004
First Named Inventor	Allen, <i>et al.</i>
Group Art Unit	1615
Examiner Name	Kishore, Gollamudi
Attorney Docket No.	55325-8148.US07

Sheet 1 of 2

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			
	1.	5,426,112		Zagon <i>et al.</i>	06/20/05	
	2.	5,719,032		Vielkind, Juergen R.	2/17/98	
	3.	5,840,687		Harkins <i>et al.</i>	11/24/98	
	4.	6,056,973		Allen <i>et al.</i>	5/2/00	
	5.	6,129,916		Chang, Tse Wen	10/10/00	
	6.	6,224,903		Martin <i>et al.</i>	5/1/01	
	7.	6,936,272		Martin <i>et al.</i>	8/30/05	
	8.	7,122,202		Allen <i>et al.</i>	10/17/06	
	9.	2003/0215490	A1	Allen <i>et al.</i>	11/20/03	
	10.	2004/0191307	A1	Allen <i>et al.</i>	9/30/04	
	11.	2004/0191250	A1	Allen <i>et al.</i>	9/30/04	
	12.	2005/0136064	A1	Allen <i>et al.</i>	6/23/05	
	13.	2005/0169880	A1	Glick <i>et al.</i>	8/4/05	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
	14.	EPO	0 932 391	B1	Sequus Pharm., Inc.	5/2/03		
	15.	PCT	WO 94/22429	A3	Liposome Technology, Inc.	09/29/94		
	16.	PCT	WO 98/16202	A3	Sequus Pharm., Inc.	4/23/98		

EXAMINER /Gollamudi Kishore/

DATE CONSIDERED

06/24/2009

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Form PTO-1449 (Modified) (Use several sheets if necessary)				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/821,021
				Confirmation Number	9232
				Filing Date	April 7, 2004
				First Named Inventor	Allen, <i>et al.</i>
				Group Art Unit	1615
Examiner Name	Kishore, Gollamudi				
Attorney Docket No.	55325-8148.US07				
Sheet	2	of	2		

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T	
	17.	Ahmad <i>et al.</i> , "Antibody-mediated Specific Binding and Cytotoxicity of Liposome-entrapped Doxorubicin to Lung Cancer Cells <i>in Vitro</i> ", <i>Cancer Research</i> , <u>52</u> :4817-4820 (1992).		
	18.	Allen <i>et al.</i> , "Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives <i>in vivo</i> ", <i>Biochimica et Biophysica Acta</i> , <u>1066</u> :29-36 (1991).		
	19.	Behr, Jean-Paul, "Gene Transfer with Synthetic Cationic Amphiphiles: Prospects for Gene Therapy", <i>Bioconjugate Chem.</i> , <u>5</u> :382-389, (1994).		
	20.	Blaese <i>et al.</i> , "Vectors in cancer therapy: how will they deliver?", <i>Cancer Gene Therapy</i> , <u>2</u> (4):291-297, (1995).		
	21.	Carter <i>et al.</i> , "High Level <i>Escherichia coli</i> Expression and Production of a Bivalent Humanized Antibody Fragment", <i>BioTechnology</i> , <u>10</u> :163-167, (1992).		
	22.	Felgner <i>et al.</i> , "Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations", <i>The Journal of Biological Chemistry</i> , <u>269</u> (4):2550-2561, (1994).		
	23.	Gao <i>et al.</i> , "Cationic liposome-mediated gene transfer", <i>Gene Therapy</i> , <u>2</u> :710-722, (1995).		
	24.	Heath, T., <i>et al.</i> , <i>Experimental Cell Research</i> , <u>149</u> :163-175 (1983).		
	25.	Klibanov, A.L., <i>et al.</i> , <i>FEBS Letters</i> , <u>268</u> (1):235-237 (1990).		
	26.	Lear and Rafalski, Viral Fusion Mechanisms, J.Bentz (ed), CRC Press, Boca Raton, pgs. 56-66 (1993).		
	27.	Lee and Low, <i>Biochimica et Biophysica ACTA</i> , <u>1233</u> :134-144 (1995).		
	28.	Maruyama, K., <i>et al.</i> , <i>Proc Natl Acad Sci USA</i> , <u>87</u> :5744, (1990).		
	29.	Mayhew <i>et al.</i> , "Role of Cholesterol in Enhancing the Antitumor Activity of Cytosine Arabinoside Entrapped in Liposomes", <i>Cancer Treatment Reports</i> , <u>63</u> (11-12):1923-1928, (1979).		
	30.	Plum <i>et al.</i> , "Condensation of DNA by Trivalent Cations. 2. Effects of Cation Structure", <i>Biopolymers</i> , <u>30</u> :631-643, (1990).		
	31.	Remy <i>et al.</i> , "Gene Transfer with a Series of Lipophilic DNA-Binding Molecules", <i>Bioconjugate Chem.</i> , <u>5</u> :647-654, (1994).		
	32.	Sinha, D., <i>et al.</i> , <i>Biochem. Biophys. Res. Comm.</i> , <u>90</u> (2):554 (1979).		

EXAMINER	/Gollamudi Kishore/	DATE CONSIDERED	06/24/2009
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).			